BPG is committed to discovery and dissemination of knowledge
Articles in Press
7/3/2026 6:16:25 AM | Browse: 4 | Download: 0
| Category |
Psychiatry |
| Manuscript Type |
Prospective Study |
| Article Title |
Real-world safety and effectiveness of lurasidone in Chinese children and adolescents with schizophrenia: Findings from a prospective cohort
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Lei Zhang, Yu-Mei Wei and Yi-Feng Shen |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Collaborative Innovation Center Project of Translational Medicine, Shanghai Jiaotong University School of Medicine |
No. TM202116PT |
| Clinical Research Plan of SHDC |
No. SHDC2022CRS032 |
| Sumitomo Pharma (Suzhou) Co.,Ltd |
|
|
| Corresponding Author |
Yi-Feng Shen, Shanghai Key Laboratory of Psychotic Disorders, Shanghai Clinical Research Center for Mental Health, School of Medicine, Shanghai Jiao Tong University, No. 600 Wanping Nan Road, Shanghai 200030, China. shenyifeng@yahoo.com |
| Key Words |
Schizophrenia; Children and adolescents; Lurasidone; Safety; Effectiveness |
| Core Tip |
This is the first study to specifically evaluate lurasidone monotherapy in a substantial cohort of Chinese children and adolescents with schizophrenia, providing essential evidence on real-world dosing patterns, safety, and effectiveness. Pediatric patients were initiated on lurasidone at lower doses but underwent more rapid titration, ultimately reaching a slightly higher mean final and daily dose than adults. Lurasidone 40-80 mg/day was well tolerated with low rates of adverse events, suggesting potential clinical improvement, particularly in patients with more severe depressive symptoms. These findings suggest that lurasidone may be a promising treatment option for Chinese pediatric patients with schizophrenia. |
| Citation |
Zhang L, Wei YM, Shen YF. Real-world safety and effectiveness of lurasidone in Chinese children and adolescents with schizophrenia: Findings from a prospective cohort. World J Psychiatry 2026; In press
|
 |
Received |
|
2026-03-16 03:17 |
 |
Peer-Review Started |
|
2026-03-16 03:19 |
 |
First Decision by Editorial Office Director |
|
2026-03-20 10:00 |
 |
Return for Revision |
|
2026-03-20 10:00 |
 |
Revised |
|
2026-04-16 03:24 |
 |
Publication Fee Transferred |
|
2026-04-20 06:32 |
 |
Second Decision by Editor |
|
2026-07-03 02:38 |
 |
Second Decision by Editor-in-Chief |
|
|
 |
Final Decision by Editorial Office Director |
|
2026-07-03 06:16 |
 |
Articles in Press |
|
2026-07-03 06:16 |
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
|
| ISSN |
2220-3206 (online) |
| Open Access |
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.